SCHEMBL3614801

SCHEMBL3614801

Cn1nc(C2CC2)c(C=O)c1Sc1cccc(O)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
MGLL Q99685 4/20 0.34
PDE4D Q08499 1/20 0.33
PDE7A Q13946 1/20 0.33
FYN P06241 1/20 0.33
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
DRD2 P14416 2/20 0.31
HSD17B2 P37059 2/20 0.31
DRD3 P35462 1/20 0.30
HSD17B1 P14061 1/20 0.30
OPRM1 P35372 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609583 0.82 MAPT (0.43) NPSR1MAPTHPGDHTTPDE4D
SCHEMBL3617878 0.72 HSD17B2 (0.36) NPSR1MAPTHPGDHTTPDE4D
SCHEMBL29052280 0.69
SCHEMBL3612443 0.69 HSD17B2 (0.40) NPSR1MAPTHPGDPDE4DPDE7A
SCHEMBL3600937 0.65 SMN1; SMN2 (0.52) NPSR1MAPTHPGDPDE4DSMN1; SMN2
SCHEMBL963602 0.63 L3MBTL1 (0.36) SMN1; SMN2L3MBTL1CYP1A2CYP2C9CYP2C19
SCHEMBL23134273 0.62
SCHEMBL31281467 0.61 CA12 (0.58) MGLLSMN1; SMN2TDP1HSD17B2HSD17B1
SCHEMBL2239504 0.61 CA12 (0.58) MGLLSMN1; SMN2TDP1HSD17B2HSD17B1
SCHEMBL2727753 0.60 ALDH5A1 (0.47) MAPTMGLLSMN1; SMN2HSD17B2HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R NPSR1 2509/4885MAPT 3754/4885HPGD 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.